Caxton Associates (New York)’s Halozyme HALO Stock Holding History

Caxton Associates (New York)’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-34,432	Closed	-$1.97M	–	567
2024 Q3	$1.97M	Buy	34,432 +9,000	+35%	+$516K	0.07%	121
2024 Q2	$1.33M	Buy	+25,432	New	+$1.12M	0.05%	208
2024 Q1	–	Sell	-8,281	Closed	-$306K	–	504
2023 Q4	$306K	Buy	+8,281	New	+$312K	0.02%	398
2023 Q2	–	Sell	-13,035	Closed	-$498K	–	561
2023 Q1	$498K	Buy	+13,035	New	+$611K	0.08%	265
2022 Q3	–	Sell	-9,782	Closed	-$430K	–	558
2022 Q2	$430K	Buy	+9,782	New	+$423K	0.04%	311
2021 Q1	–	Sell	-10,471	Closed	-$447K	–	441
2020 Q4	$447K	Buy	+10,471	New	+$376K	0.03%	70
2020 Q3	–	Sell	-49,216	Closed	-$1.32M	–	397
2020 Q2	$1.32M	Buy	+49,216	New	+$1.11M	0.12%	61
2020 Q1	–	Sell	-32,348	Closed	-$574K	–	479
2019 Q4	$574K	Buy	+32,348	New	+$560K	0.08%	150

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caxton Associates (New York)'s HALO Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Halozyme (HALO) in Q4 2024, closing a stake of 34,432 shares — an estimated $1.97M sold.

Caxton Associates (New York) first reported a position in HALO in Q4 2019 and held it in 8 quarters. The position peaked at $1.97M in Q3 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

Caxton Associates (New York) reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
Caxton Associates (New York) sold 34,432 Halozyme shares in Q4 2024, an estimated $1.97M.
Caxton Associates (New York) first reported a position in Halozyme in Q4 2019 and held it in 8 quarters.
Caxton Associates (New York)'s Halozyme position peaked at $1.97M in Q3 2024.
508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.